Serum levels of IL-17A in patients with relapsing–remitting multiple sclerosis treated with interferon-β

Abstract

RRMS patients with high serum IL-17A levels do not respond well to IFN-β therapy and have shorter MS duration compared to patients with low IL-17A levels. This response is not influenced by the presence of BAbs.